nafamostat has been researched along with Experimental Hepatoma in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haruki, K | 1 |
| Shiba, H | 1 |
| Fujiwara, Y | 1 |
| Furukawa, K | 1 |
| Iwase, R | 1 |
| Uwagawa, T | 1 |
| Misawa, T | 1 |
| Ohashi, T | 1 |
| Yanaga, K | 1 |
| Kimura, T | 1 |
| Fuchimoto, S | 1 |
| Iwagaki, H | 1 |
| Orita, K | 1 |
2 other studies available for nafamostat and Experimental Hepatoma
| Article | Year |
|---|---|
Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice.
Topics: Adenoviridae; Animals; Apoptosis; Benzamidines; Genetic Therapy; Guanidines; Humans; Liver Neoplasms | 2013 |
[The inhibitory effect of nafamostat mesilate (FUT-175) on liver metastasis].
Topics: Animals; Benzamidines; Collagenases; Colonic Neoplasms; Fibrinolysin; Guanidines; Liver Neoplasms, E | 1993 |